The same group further assessed this dual-targeting approach in hepatocellular carcinoma cells and K-ras mutant NSCLC cells, also showing an increased radiosensitization in vitro and in vivo compared to either agent alone. This evidence concerns the gene KRAS and hepatocellular carcinoma.